Status:
COMPLETED
Pharmacogenomics of Paclitaxel in Ovarian Cancer
Lead Sponsor:
University of Southern Denmark
Collaborating Sponsors:
Danish Clinical Intervention Research Academy
Ministry of the Interior and Health, Denmark
Conditions:
Ovarian Neoplasms
Fallopian Tube Neoplasms
Eligibility:
FEMALE
18+ years
Brief Summary
This study will try to determine whether or not certain genes are responsible for the huge variation in toxicity and effect observed between patients treated with paclitaxel (chemotherapeutic drug). S...
Detailed Description
Paclitaxel is an antineoplastic drug used in the treatment of ovarian cancer. The effect and toxicity is unpredictable in the individual patient. Paclitaxel is removed (eliminated) from the organism b...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients enrolled in "TC/TEC" in Denmark, Sweden or Norway
- Patients enrolled in "OVAR-9" in Denmark, Sweden or Norway
Exclusion
Key Trial Info
Start Date :
December 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2010
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT00415207
Start Date
December 1 2006
End Date
December 1 2010
Last Update
August 8 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Pharmacology, University of Southern Denmark
Odense, Denmark